{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-197047","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.089884+00:00","generated_at":"2026-05-31T11:18:49.481315+00:00","sec_items":["2.05","5.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AN2 discontinues EBO-301 MAC lung study, cuts ~50% workforce, shifts pipeline focus","bullets":["Phase 2/3 EBO-301 study discontinued; sputum culture conversion at Month 6: 13.2% vs 10.0% (p=0.64).","Reduction in force of ~50% of employees; expects $2-3M in severance charges.","CMO Paul Eckburg departs Aug 30, 2024; will continue as consultant with vesting.","Company shifts focus to boron chemistry platform; plans Phase 1 for Chagas, Phase 2 for melioidosis.","Cost savings expected to extend cash runway through 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-197047","json":"https://secwatch.observer/filing/0001193125-24-197047.json","markdown":"https://secwatch.observer/filing/0001193125-24-197047.md","text":"https://secwatch.observer/filing/0001193125-24-197047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000119312524197047/0001193125-24-197047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000119312524197047/d865374d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:18:49.481315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"be08bd8817","claim":"Paul Eckburg departed as Chief Medical Officer at AN2 Therapeutics, Inc..","evidence_excerpt":"Paul Eckburg, M.D., the Company’s Chief Medical Officer, will depart the Company effective as of August 30, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312524197047/0001193125-24-197047-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"e1cd3a7ffa6f1b47ba5cbb6c73f92f1c312109cc","claim":"AN2 Therapeutics, Inc. announced a restructuring with charges of approximately $2-$3 million (approximately 50% of the Company's employee workforce).","evidence_excerpt":"On August 7, 2024, the Board of Directors of AN2 Therapeutics, Inc. (the “Company”) approved a reduction in force that is intended to result in the termination of approximately 50% of the Company’s employee workforce.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312524197047/0001193125-24-197047-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $2-$3 million"},{"label":"Headcount","value":"approximately 50% of the Company's employee workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}